Yongan Pharmaceutical announced that the company plans to absorb and merge its wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd. After the merger is completed, Ling An Technology will cancel, and all of its assets, claims, debts, business, personnel, and all other rights and obligations will be inherited by the company in accordance with law. Main financial data of Ling An Technology for the most recent year and phase 1: December 31, 2024, total assets of 180 million yuan, total liabilities of 83.7119 million yuan, net assets of 96.22,800 yuan; operating income of 704.711 million yuan and net profit of 11.154,300 yuan from January to September 2025.

Zhitongcaijing · 5d ago
Yongan Pharmaceutical announced that the company plans to absorb and merge its wholly-owned subsidiary Hubei Ling'an Technology Co., Ltd. After the merger is completed, Ling An Technology will cancel, and all of its assets, claims, debts, business, personnel, and all other rights and obligations will be inherited by the company in accordance with law. Main financial data of Ling An Technology for the most recent year and phase 1: December 31, 2024, total assets of 180 million yuan, total liabilities of 83.7119 million yuan, net assets of 96.22,800 yuan; operating income of 704.711 million yuan and net profit of 11.154,300 yuan from January to September 2025.